The merger

Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections, an additional pharmaceutical project with patent rights for the treatment of tuberculosis is acquired.


Hamlet Pharma Soon To Be Hamlet BioPharma Presents At Aktiespararnas Capital Market Day On June 12 In Stockholm

We develop cancer treatment with no or low side effects

Hamlet Pharma provides new therapeutic solutions for targeting and killing tumor cells with greater precision.

Discover Hamlet Pharma

The film about HAMLET – English

The film about HAMLET – Svenska

european union flag

Hamlet Pharma is part of the European Union Horizon 2020 program.

Read more

Latest news

August 28, 2023 in Financial, News, Pressmeddelande

Q4 Year-end Report July 2022-June 2023

Hamlet Pharma Q4 Year-end Report July 2022-June 2023 >>
Read More
August 18, 2023 in Financial, News, Pressmeddelande

Hamlet Pharma AB (publ) genomför namnbyte till Hamlet BioPharma AB (publ)

Hamlet Pharma AB (publ) ("Bolaget") har genomfört namnbyte till Hamlet BioPharma AB (publ), vilket röstades igenom på extra bolagsstämman som avhölls den 11 augusti 2023.…
Read More
August 11, 2023 in Financial, News, Pressmeddelande

Kommuniké Från Extra Bolagsstämman i Hamlet Pharma AB

Pressmeddelande Malmö 11 augusti 2023  Som tidigare meddelats har Bolagsverket registrerat fusionen mellan Hamlet Pharma och SelectImmune Pharma. Detta innebär att Hamlet Pharma och SelectImmune Pharma…
Read More
Read more news

Executive Summary

Hamlet Pharma provides new therapeutic solutions for targeting and killing tumor cells with greater precision.

  • The parent compound HAMLET shows broad anti-tumor effects in animal models and clinical trials
  • The 2nd generation, synthetic drug candidate Alpha1H kills a variety of cancer cells.
  • Therapeutic efficacy of Alpha1H has been demonstrated in controlled clinical trials.
  • Recent successful outcomes include
    • a placebo-controlled study of bladder cancer, showing therapeutic efficacy without detectable toxicity
      (Link: Nature Communications)
    • A dose escalation study, showed increased efficacy with higher doses of Alpha1H.
  • Hamlet Pharma’s IP includes about 50 patents and patent applications, world-wide.
  • Hamlet Pharma’s drug development pipeline includes:
    • Alpha1H for brain tumors (with international key opinion leaders).
    • Bovine HAMLET, BAMLET, is under development for clinical trials in colon cancer and oral cancer.
    • BAMLET is also of interest as a health food concept.

Hamlet Pharma is looking for partnering/investment to take the new drugs to the market.

Our project portfolio

Drug candidate Alpha1H

Our drug candidate Alpha1H kills tumor cells quickly and selectively. The strong effects have been validated in cell models, animal models and in treated patients, where the response can be measured already within a few hours.

Bladder cancer

Each year, around 500,000 patients worldwide are diagnosed with bladder cancer, and this number is rising. Alpha1H has been shown to kill tumor cells and significantly reducing tumor size, without harming healthy tissues, with low side effects in patients. Our clinical trials program is now moving towards Phase III.

Copyright: Krames StayWell

Brain tumor

Early studies in animal models have shown that infusion of Alpha1H into the brain markedly delayed the progression of tumors. In a collaboration with Neurochase Ltd. in the UK, Alpha1H is now tested further to evaluate its potential of treating brain tumors, using proprietary method and technology of administrating drugs locally, with great precision, into the brain.

Source: Diffuse Midline Gliomas Diagnosis and Treatment, by the National Cancer Institute.

Drug Candidate BAMLET

BAMLET is a protein-complex formed by alpha lactalbumin from cow’s milk, and oleic acid. Like Alpha1H, BAMLET effectively kills cancer cells and has shown effects against growing tumor tissue. The company intends to establish production of BAMLET primarily for clinical studies for the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.

Colon cancer

Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone. Daily, long-term treatment with BAMLET in the drinking water inhibits intestinal tumor development in mice genetically susceptible to intestinal tumors. Target groups for BAMLET treatment are patients at risk of developing colon cancer and patients who already have the disease.

Oral cancer

Hamlet Pharma intends to investigate whether BAMLET can be developed into a treatment for oral cancer.

Presentation and films

3rd International Donor Milk Research Congress
Milan, Italy

Presentation by Catharina Svanborg (English)

See all media

Financial reports


Q4 Year-end report
July 2022 – June 2021


Q3 Interim report
January 2022 – March 2022


Q2 Interim report
October 2021 – December 2021


Q1 Interim report
July 2021 – September 2021

Read more reports

Hamlet Pharma is listed on Spotlight Stockmarket

Our story

A research group in Lund, led by Professor Catharina Svanborg discovered in 1995 that a component of human breast milk kills tumor cells without harming mature, healthy cells.

Since the discovery, the research team has successfully worked to characterize the HAMLET structure, its mechanisms and treatment effects in animal models and in patients. HAMLET´s tumor killing abilities have since the discovery been confirmed by several international research groups working on different aspects of HAMLET.

The results have been published in prestigious journals like The New England Journal of Medicine, GUT, Nature Communication and PNAS (Proceedings of the National Academy of Science, USA).

Read more about us

Our science


Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

Nature Communications


A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate

Molecular and Cellular Oncology

Bladder cancer therapy without toxicity—A dose-escalation study of alpha1-oleate

International Journal of Cancer

See all publications

Our team

The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. HAMLET’s aim is to prove the efficacy of HAMLET therapy and to develop drugs that kill tumour cells with greater precision than current drugs.

Board of Directors

Catharina Svanborg

Chairman Of The Board

Ulla Trägårdh

Member of the Board

Bill Hansson

Member of the board

Helena Lomberg

Member of the Board

Executive Team

Mats Persson

Senior Advisor

Martin Erixon